Bertil Damato1, Laura Hope-Stone2, Bruce Cooper3, Steve L Brown2, Peter Salmon2, Heinrich Heimann2, Laura B Dunn4. 1. University of California San Francisco, San Francisco, California, USA; University of Liverpool, Liverpool, United Kingdom. Electronic address: Bertil.Damato@ucsf.edu. 2. University of Liverpool, Liverpool, United Kingdom. 3. University of California San Francisco, San Francisco, California, USA. 4. Stanford University, Stanford, California, USA.
Abstract
PURPOSE: To test the hypothesis that patients treated with radiotherapy for choroidal melanoma enjoy better quality of life (QoL) than patients who have undergone enucleation. METHODS: In this nonrandomized study, patients with choroidal melanoma treated at the Royal Liverpool University Hospital, Liverpool, UK, were invited to complete QoL questionnaires approximately 6 months postoperatively and then on each anniversary of their primary treatment. These instruments consisted of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-OPT30 questionnaire, Hospital Anxiety & Depression Scale, and the Functional Assessment of Cancer Treatment questionnaire. Patient-reported outcomes were correlated with demographics, ocular treatment, social factors, presenting tumor and ocular status, self-reported general health, marital status, and employment status. RESULTS: The 1596 patients were treated with radiotherapy (72.3%) or enucleation (27.7%). Enucleation was associated with male sex (χ2, P = .004), older age (t test, P < .001), larger tumor diameter (t test, P < .001), monosomy 3 (χ2, P < .001), depression (linear regression, 95% confidence interval [CI], .17 to 1.01), and reduced physical and functional well-being (linear regression, 95% CI, -1.14 to -0.12 and -1.96 to -0.47), respectively. Poor QoL was attributed to the ocular disease by 21% and 20% of enucleated and irradiated patients, respectively (χ2, P = .938). CONCLUSIONS: Patient-reported outcomes and QoL were worse in patients who had undergone primary enucleation for choroidal melanoma. These outcomes may partly have been caused by factors predisposing to enucleation rather than enucleation itself, because enucleated patients tended to be older, with more advanced disease at presentation, and a worse prognosis for survival. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
PURPOSE: To test the hypothesis that patients treated with radiotherapy for choroidal melanoma enjoy better quality of life (QoL) than patients who have undergone enucleation. METHODS: In this nonrandomized study, patients with choroidal melanoma treated at the Royal Liverpool University Hospital, Liverpool, UK, were invited to complete QoL questionnaires approximately 6 months postoperatively and then on each anniversary of their primary treatment. These instruments consisted of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-OPT30 questionnaire, Hospital Anxiety & Depression Scale, and the Functional Assessment of Cancer Treatment questionnaire. Patient-reported outcomes were correlated with demographics, ocular treatment, social factors, presenting tumor and ocular status, self-reported general health, marital status, and employment status. RESULTS: The 1596 patients were treated with radiotherapy (72.3%) or enucleation (27.7%). Enucleation was associated with male sex (χ2, P = .004), older age (t test, P < .001), larger tumor diameter (t test, P < .001), monosomy 3 (χ2, P < .001), depression (linear regression, 95% confidence interval [CI], .17 to 1.01), and reduced physical and functional well-being (linear regression, 95% CI, -1.14 to -0.12 and -1.96 to -0.47), respectively. Poor QoL was attributed to the ocular disease by 21% and 20% of enucleated and irradiated patients, respectively (χ2, P = .938). CONCLUSIONS:Patient-reported outcomes and QoL were worse in patients who had undergone primary enucleation for choroidal melanoma. These outcomes may partly have been caused by factors predisposing to enucleation rather than enucleation itself, because enucleated patients tended to be older, with more advanced disease at presentation, and a worse prognosis for survival. NOTE: Publication of this article is sponsored by the American Ophthalmological Society.
Authors: Cari Davies; Stephen Lloyd Brown; Peter Fisher; Laura Hope-Stone; Debra Fisher; Andrew Morgan; Mary Gemma Cherry Journal: Eye (Lond) Date: 2022-08-08 Impact factor: 4.456
Authors: Johannes Gollrad; Christopher Rabsahl; Antonia M Joussen; Andrea Stroux; Volker Budach; Dirk Böhmer; Alexander Böker Journal: Ocul Oncol Pathol Date: 2021-11-08
Authors: Catharina Busch; Matus Rehak; Ahmad Alfaar; Anas Saad; Piotr Chlad; Omneya Ezzat Elsherif; Mohammad Elshami Journal: Int Ophthalmol Date: 2022-07-11 Impact factor: 2.029
Authors: Christopher A Barker; Anna Kozlova; Alexander N Shoushtari; Jennifer L Hay; Jasmine H Francis; David H Abramson Journal: Ocul Oncol Pathol Date: 2019-09-27
Authors: Marina Marinkovic; Lennart J Pors; Vincent van den Berg; Femke P Peters; Ann Schalenbourg; Leonidas Zografos; Alessia Pica; Jan Hrbacek; Sjoerd G Van Duinen; T H Khanh Vu; Jaco C Bleeker; Coen R N Rasch; Martine J Jager; Gregorius P M Luyten; Nanda Horeweg Journal: Cancers (Basel) Date: 2021-12-13 Impact factor: 6.639